Volume 13, Issue 4 (5-2015)
IJRM 2015, 13(4): 221-226 |
Back to browse issues page
Mesut Yıldız1 
, Mehmet Vural2 , Mehmet Emin Erdal3 , Özlem İzci Ay3 , Şenay Görücü Yılmaz3 , İbrahim Fatih Karababa4 , Salih Selek * 5
, Mehmet Vural2 , Mehmet Emin Erdal3 , Özlem İzci Ay3 , Şenay Görücü Yılmaz3 , İbrahim Fatih Karababa4 , Salih Selek * 5
1- Department of Psychiatry, Faculty of Medicine, Gaziosmanpaşa University, Tokat, Turkey
2- Department of Obstetrics and Gynecology, Faculty of Medicine, Harran University, Sanliurfa, Turkey
3- Department of Medical Biology and Genetics, Faculty of Medicine, Mersin University, Mersin, Turkey
4- Department of Psychiatry, Faculty of Medicine, Harran University, Sanliurfa, Turkey
5- Department of Psychiatry and Behavıoral Sciences, University of Texas Health Science Center at Houston, Houston, Texas, USA , drselek@yahoo.com
2- Department of Obstetrics and Gynecology, Faculty of Medicine, Harran University, Sanliurfa, Turkey
3- Department of Medical Biology and Genetics, Faculty of Medicine, Mersin University, Mersin, Turkey
4- Department of Psychiatry, Faculty of Medicine, Harran University, Sanliurfa, Turkey
5- Department of Psychiatry and Behavıoral Sciences, University of Texas Health Science Center at Houston, Houston, Texas, USA , drselek@yahoo.com
Abstract: (2321 Views)
Background: Premenstrual dysphoric disorder (PMDD) is a mood disorder characterized with physical and affective symptoms during the luteal phase of susceptible women.
Objective: The aim of this study was to investigate the association of Dopamine D3 receptor ( DRD3 ) polymorphism, and Cannabinoid receptor Type 1 ( CNR1 ) polymorphism with PMDD.
Materials and Methods: Fifty one participants with documented PMDD according to the DSM IV criteria and 51 healthy controls were included in this cross sectional study. Symptom severity was measured with daily self-rating, monthly premenstrual assessment forms and psychiatric interviews. The genotyping of DRD3 receptor and Cannabinoid type 1 receptors were performed using Taqmanfluorogenic assay method.
Results: Distribution of DRD3 and CNR1 polymorphism was not different between patients and controls.
Conclusion: These findings do not support a major role of DRD3 , and CNR1 polymorphisms in contributing to susceptibility to premenstrual dysphoric disorder.
Objective: The aim of this study was to investigate the association of Dopamine D3 receptor ( DRD3 ) polymorphism, and Cannabinoid receptor Type 1 ( CNR1 ) polymorphism with PMDD.
Materials and Methods: Fifty one participants with documented PMDD according to the DSM IV criteria and 51 healthy controls were included in this cross sectional study. Symptom severity was measured with daily self-rating, monthly premenstrual assessment forms and psychiatric interviews. The genotyping of DRD3 receptor and Cannabinoid type 1 receptors were performed using Taqmanfluorogenic assay method.
Results: Distribution of DRD3 and CNR1 polymorphism was not different between patients and controls.
Conclusion: These findings do not support a major role of DRD3 , and CNR1 polymorphisms in contributing to susceptibility to premenstrual dysphoric disorder.
Type of Study: Original Article |
References
1. Angst J, Sellaro R, Merikangas KR, Endicott J. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001: 104; 110-116. [DOI:10.1034/j.1600-0447.2001.00412.x]
2. American Psychiatric Association, Diagnostic and statistical manual of mental disorders: DSM IV. 4th Ed. Washington (DC), American Psychiatric Publishing; 1994.
3. Henshaw CA. PMS: diagnosis, aetiology, assessment and management Revisiting Premenstrual syndrome. Adv PsychiatrTreatment 2007: 13; 139-146. [DOI:10.1192/apt.bp.106.003392]
4. Halbreich U, Tworek H. Altered serotonergic activity in women with dysphoric premenstrual syndrome. Int J Psychiatry Med 1993; 23; 1-27. [DOI:10.2190/J2W0-RTGD-NYKK-FF77]
5. Parry BL. The role of central serotonergic dysfunction in the aetiology of premenstrual dysphoric disorder: therapeutic implications. CNS Drugs 2001; 15: 277-285. [DOI:10.2165/00023210-200115040-00003]
6. Ho H, Olsson M, Westberg L, Melke J, Erikkson E. The serotonin reuptake inhibitor fluoxetine reduces sex steroid-related aggression in female rats: an animal model of premenstrual irritability? Neuropsychopharmacology 2001; 24: 502-510. [DOI:10.1016/S0893-133X(00)00219-0]
7. Roca CA, Schmidt P, Smith MJ, Danaceau MA, Murphy DL, Rubinow DR. Effects of meter-goline on symptoms in women with premenstrual dysphoric disorder. Am J Psychiatry 2002; 159: 1876-1881. [DOI:10.1176/appi.ajp.159.11.1876]
8. Yonkers KA. The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry 1997: 58; 1-7.
9. Klatzkin RR, Lindgren ME, Forneris CA, Girdler SS. Histories of major depression and premenstrual dysphoric disorder: evidence for phenotypic differences. Biol Psychol 2010; 84: 235-247. [DOI:10.1016/j.biopsycho.2010.01.018]
10. Payne JL, Roy PS, Murphy-Eberenz K, Weissmann MM, Swartz KL, McInnis MG, et al. Reproductive cycle-associated mood symptoms in women with major depression and bipolar disorder. J Affect Disord 2007; 99: 221-229. [DOI:10.1016/j.jad.2006.08.013]
11. Kim DR, Gyulai L, Freeman EW, Morrison MF, Baldassano C, Dube B. Premenstrual dysphoric disorder and psychiatric co-morbidity. Arch Womens Ment Health 2004; 7: 37-47. [DOI:10.1007/s00737-003-0027-3]
12. Kendler KS, Karkowski LM, Corey LA, Neale MC. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry 1998: 155; 1234-1240. [DOI:10.1176/ajp.155.9.1234]
13. Kendler KS, Silberg JL, Neale MC, Kessler RC, Heath AC, Eaves LJ. Genetic and environmental factors in the aetiology of menstrual, premenstrual and neurotic symptoms: a population based twin study. Psychol Med 1992: 22; 85-100. [DOI:10.1017/S0033291700032761]
14. Wilson CA, Turner CW, Keye WR Jr. Firstborn adolescent daughters and mothers with and without premenstrual syndrome: a comparison. J Adolesc Health 1991: 12; 130-137. [DOI:10.1016/0197-0070(91)90455-U]
15. Heils A, Teufel A, Petri S, Seemann M, Bengel D, Balling U, et al. Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene. J Neural Transm Gen Sect 1995: 102: 247–254. [DOI:10.1007/BF01281159]
16. Magnay JL, El-Shourbagy M, Fryer AA, O'Brien S, Ismail KM. Analysis of the serotonin transporter promoter rs25531 polymorphism in premenstrual dysphoric disorder. Am J Obstet Gynecol 2010: 203: 181. [DOI:10.1016/j.ajog.2010.02.043]
17. Dhingra V, Magnay JL, O'Brien PM, Chapman G, Fryer AA, Ismail KM. Serotonin receptor 1A C(-1019)G polymorphism associated with premenstrual dysphoric disorder. Obstet Gynecol 2007: 110: 788-792. [DOI:10.1097/01.AOG.0000284448.73490.ac]
18. Damberg M. Transcription factor AP-2 and monoaminergic functions in the central nervous system. J Neural Transm 2005; 112: 1281-1296. [DOI:10.1007/s00702-005-0325-1]
19. Anney RJ, Rees MI, Bryan E, Spurlock G, Williams N, Norton N, et al. Characterisation, mutation detection, and association analysis of alternative promoters and 5' UTRs of the human dopamine D3 receptor gene in schizophrenia. Mol Psychiatry 2002; 7: 493-502. [DOI:10.1038/sj.mp.4001003]
20. Lammers CH, Diaz J, Schwartz JC, Sokoloff P. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry 2000; 5: 378-388. [DOI:10.1038/sj.mp.4000754]
21. Sokoloff P Diaz J, FollB L, Guillin O, Leriche L, Bezard E, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006: 5; 25-43. [DOI:10.2174/187152706784111551]
22. Talkowski ME, Mansour H, Chowdari KV, Wood J, Butler A, Varma PG et al. Novel, replicated associations between dopamine D3 receptor gene polymorphisms and schizophrenia in two independent samples. Biol Psychiatry 2006; 60: 570-577. [DOI:10.1016/j.biopsych.2006.04.012]
23. Tsuchimine S, Yasui-Furukori N, Nakagami T, Sato Y, Kaneko S. DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study. J Clin Psychopharmacol 2012; 32: 724-726. [DOI:10.1097/JCP.0b013e318267b6da]
24. Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD et al. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet 2008; 17: 2834-2848. [DOI:10.1093/hmg/ddn181]
25. Hawi Z, Segurado R, Conroy J, Sheehan K, Lowe N, Kirley A et al. Preferential transmission of paternal alleles at risk genes in attention-deficit/hyperactivity disorder. Am J Hum Genet 2005; 77: 958-965. [DOI:10.1086/498174]
26. Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 2008; 1 (Suppl.): 10-14. [DOI:10.1111/j.1365-2826.2008.01671.x]
27. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990: 346; 561-564. [DOI:10.1038/346561a0]
28. Ashton CH, Moore PB. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand 2011: 124; 250-261. [DOI:10.1111/j.1600-0447.2011.01687.x]
29. Çınar ÖG, Çınar R. An overview of cannabinoid receptor 1 (CB1) and therapeutic approaches-II. Journal of MarmaraUniversity Institute of Health Sciences 2012; 2: 1-8.
30. Benyamina A, Bonhomme-Faivre L, Picard V, Sabbagh A, Richard D, Blecha L et al. Association between ABCB1 C3435Tpolymorphism and increased risk of cannabis dependence. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1270-1274. [DOI:10.1016/j.pnpbp.2009.07.016]
31. Proudnikov D, Kroslak T, Sipe JC, Randesi M, Li D, Hamon S, et al. Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1. Pharmacogenomics J 2010; 10: 232-242. [DOI:10.1038/tpj.2009.59]
32. Barrero FJ, Ampuero I, Morales B, Vives F, de Dios Luna Del Castillo J, Hoenicka J et al. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J 2005; 5: 135-141. [DOI:10.1038/sj.tpj.6500301]
33. Monteleone P, Bifulco M, Maina G, Tortorella A, Gazzerro P, Proto MC, et al. Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol Res 2010; 61: 400-404. [DOI:10.1016/j.phrs.2010.01.002]
34. Lu AT, Ogdie MN, Jarvelin MR, Moilanen IK, Loo SK, McCracken JT, et al. Association of the cannabinoid receptor gene(CNR1) with ADHD and post-traumatic stress disorder. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1488-1494. [DOI:10.1002/ajmg.b.30693]
35. Monteleone P, Bifulco M, Di Filippo C, Gazzerro P, Canestrelli B, Monteleone F, et al. Association of CNR1 and FAAH endocannabinoid gene polymorphisms with anorexia nervosa and bulimia nervosa: evidence for synergistic effects. Genes Brain Behav 2009; 8: 728-732. [DOI:10.1111/j.1601-183X.2009.00518.x]
36. Ho BC, Wassink TH, Ziebell S, Andreasen NC. Cannabinoid receptor 1 gene polymorphisms andmarijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr Res 2011; 128: 66-75. [DOI:10.1016/j.schres.2011.02.021]
37. Ehlers CL, Slutske WS, Lind PA, Wilhelmsen KC. Association between single nucleotidepolymorphisms in the cannabinoid receptor gene (CNR1) and impulsivity in southwest CaliforniaIndians. Twin Res Hum Genet 2007; 10: 805-811. [DOI:10.1375/twin.10.6.805]
38. Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health 2006; 9: 41-49. [DOI:10.1007/s00737-005-0103-y]
39. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research 1988; 16: 1215. [DOI:10.1093/nar/16.3.1215]
40. Adams DH, Close S, Farmen M, Downing AM, Breier A, Houston JP. Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder. Hum Psychopharmacol. 2008; 23: 267-274. [DOI:10.1002/hup.930]
41. Schosser A, Gaysina D, Cohen-Woods S, Domenici E, Perry J, et al. A follow-up case-control association study of tractable (druggable) genes in recurrent major depression. Am J Med Genet B Neuropsychiatr Genet 2011; 156B: 640-650. [DOI:10.1002/ajmg.b.31204]
42. Dikeos DG, Papadimitriou GN, Avramopoulos D, Karadima G, Daskalopoulou EG, Souery D, et al. Association between the dopamine D3 receptor gene locus (DRD3) and unipolar affective disorder. Psychiatr Genet 1999; 9: 189-195. [DOI:10.1097/00041444-199912000-00005]
43. Henderson AS, Korten AE, Jorm AF, Jacomb PA, Christensen H, Rodgers B et al. COMT and DRD3 polymorphisms, environmental exposures, and personality traits related to common mental disorders. Am J Med Genet 2000; 96: 102-107.
https://doi.org/10.1002/(SICI)1096-8628(20000207)96:1<102::AID-AJMG20>3.0.CO;2-3 [DOI:10.1002/(SICI)1096-8628(20000207)96:13.0.CO;2-3]
44. Perlis RH, Adams DH, Fijal B, Sutton VK, FarmenM, Breier A, et al. Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. J Clin Psychiatry 2010; 71: 599-605. [DOI:10.4088/JCP.08m04632gre]
45. Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 2009; 34: 1257-1262. [DOI:10.1016/j.psyneuen.2009.03.013]
46. Hungund BL, Vinod KY, Kassir SA, Basavarajappa BS, Yalamanchili R, Cooper TB, et al. Upregulation of CB1 receptors and agonist-stimulated [35S] GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 2004; 9: 184-190. [DOI:10.1038/sj.mp.4001376]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |